A pharmacist-led framework for antibiotic-associated liver injury: from pharmacovigilance signals to bedside surveillance with the updated RUCAM and susceptibility markers
Evidence on culprit antibiotics and their characteristic phenotypes, the mechanistic basis of susceptibility markers including HLA-B*57:01 and slow NAT2 acetylator status, the methods and limits of disproportionality analysis, and the pharmacist's role in medication review and monitoring are brought together.